Novel Biomarkers for Kidney Disease: New Frontiers in Early Diagnosis and Monitoring

Can Pu; Wenbo Xu

doi:10.54097/eerw7s17

Authors

Can Pu
Wenbo Xu

DOI:

https://doi.org/10.54097/eerw7s17

Keywords:

Kidney Disease; Biomarkers; Early Diagnosis; Disease Monitoring; Personalized Medicine.

Abstract

Kidney diseases pose a significant threat to global public health, with early diagnosis and accurate monitoring being crucial for improving patient outcomes. However, traditional kidney disease markers such as serum creatinine and blood urea nitrogen have limitations in sensitivity and specificity. In recent years, rapid advancements in molecular biology and proteomics have led to the discovery of a series of novel biomarkers that are gradually being applied in clinical practice. This review examines novel kidney disease biomarkers, including cystatin C (Cys-C), neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1). These markers not only reflect kidney injury earlier and more accurately but may also provide important bases for kidney disease classification, severity assessment, and prognosis prediction. Additionally, this paper explores the potential of multi-marker combined detection strategies in improving diagnostic accuracy. Although these novel markers show immense potential, they still face challenges such as standardization and cost-effectiveness before widespread clinical application. Future research should focus on optimizing detection methods, establishing clinical decision thresholds, and evaluating the value of these markers in personalized medicine, thereby paving new paths for precise diagnosis and treatment of kidney diseases.

Downloads

Download data is not yet available.

References

[1] Zhao, P.T. (2024). Protective effect of cannabidiol on renal ischemia-reperfusion injury in mice [D]. Hebei North University. DOI: 10.27767/d.cnki.ghbbf.2023.000375.

[2] Lv, J., & Li, M.M. (2020). Research progress of urinary exosome microRNAs in kidney diseases [J]. Chinese Journal of Pathophysiology, 36(02):378-384.

[3] Wang, Q.S. (2017). Study on the diagnostic value of urine microalbumin/creatinine ratio, serum creatinine and serum cystatin C for early renal damage in elderly hypertensive patients [D]. Soochow University.

[4] Li, T., Wu, Y., Yuan, S.T., et al. (2024). Research progress of urinary peptide biomarkers in chronic kidney disease [J]. Hebei Medicine, 30(05):877-880.

[5] Liang, X.J. (2016). Diagnostic value of cystatin C for kidney injury [J]. International Journal of Laboratory Medicine, 37(23):3365-3367.

[6] Ashani, L., Esakky, I.E., Solomon, R., et al. (2020). Potential for Novel Biomarkers in Diabetes-Associated Chronic Kidney Disease: Epigenome, Metabolome, and Gut Microbiome [J]. Biomedicines, 8(9).

[7] Gill, K.L.S., Amatullah, N., Tran, T., et al. (2024). Contemporary considerations for nephrotoxin stewardship: Estimating kidney function and use of novel biomarkers [J]. Journal of the American College of Clinical Pharmacy, 7(8).

[8] Li, X.Y. (2017). The significance of urinary NGAL and KIM-1 in acute kidney injury before and after high-dose methotrexate treatment in children with acute lymphoblastic leukemia [D]. Zhengzhou University.

[9] Wang, H.J., Li, N., Liu, J.C., et al. (2015). Value of combined detection of multiple biological markers for early diagnosis of acute kidney injury after cardiac surgery [J]. China Medicine, 10(11):1613-1617.

[10] Wang, D., Li, J., Wang, Y. (2024). Study on the relationship between serum creatinine, urea nitrogen and cystatin C levels and the severity of nephrotic syndrome [J]. Clinical Research, 32(05):139-142.

[11] Guo, H., Li, Z.H., Wang, S.J., et al. (2018). Research progress of new biomarkers for nephrotic syndrome [J]. Hainan Medical Journal, 29(10):1430-1433.

[12] Rizvi, S.M., Kashani, B.K. (2017). Biomarkers for Early Detection of Acute Kidney Injury [J]. The Journal of Applied Laboratory Medicine: An AACC Publication, 2(3).

[13] Zhang, R.F. (2015). Evaluation and clinical significance of KIM-1, Cys C and β_2-MG detection for early renal function damage in OSAHS patients [D]. Hebei Medical University.

[14] Zang, Q. (2016). Study on the relationship between urinary liver-type fatty acid binding protein and inflammatory response in chronic kidney disease progression [D]. Hebei Medical University.

[15] Parikh, C.R., Devarajan, P., Zappitelli, M., et al. (2011). Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery [J]. Journal of the American Society of Nephrology: JASN, 22(9).

[16] Deng, N., Zhang, D.F. (2015). Research progress of early biological markers of acute kidney injury after cardiac surgery [J]. Journal of Practical Medicine, 31(22):3804-3806.

[17] Yang, X.H., Sun, R.H. (2023). Biomarkers of acute kidney injury [J]. Chinese Journal of Practical Internal Medicine, 43(12):972-977. DOI:10.19538/j. nk2023120102.

[18] De Velde, J.E., Suverein, A., Verhoeven, Y.J., et al. (2022). Biomarkers of acute kidney injury after pediatric cardiac surgery: a meta-analysis of diagnostic test accuracy [J]. European Journal of Pediatrics, 181(5).

[19] Yu, C.Z., Cao, Y., Chen, F., et al. (2013). Evaluation of diagnostic performance of glomerular filtration rate estimation equations [J]. Journal of Shanghai Jiao Tong University (Medical Science), 33(11):1496-1500.

[20] Zeng, X.H., Li, Z.X., Han, P.X., et al. (2015). Study on the relationship between urinary liver-type fatty acid binding protein and chronic kidney disease progression [J]. Labeled Immunoassays & Clinical Medicine, 22(07):672-674+686.

[21] Zhang, Y. (2012). Analysis of influencing factors of tubulointerstitial lesions in lupus nephritis and study of urinary markers [D]. Chinese PLA Medical School.

[22] Mota, A., Khonsha, F., Nejabati, H., et al. (2024). Biomarkers for Diabetic Nephropathy with a Focus on Kidney Injury Molecule-1 (KIM-1) [J]. Current Diabetes Reviews, 20(1).

[23] Meng, X., Wang, H.W. (2024). Research progress on related indicators for early diagnosis of diabetic nephropathy [J]. Journal of Shenyang Medical College, 26(02):188-192+199. DOI: 10.16753/j.cnki.1008-2344.2024.02.016.

[24] Slocum, L.J., Heung, M., Pennathur, S. (2012). Marking renal injury: can we move beyond serum creatinine? [J]. Translational Research, 159(4).

[25] Che, X.J. (2019). Analysis of related factors affecting the prognosis of allogeneic kidney transplantation and study on the mechanism of renal ischemia-reperfusion injury [D]. Shanghai Jiao Tong University. DOI: 10.27307/d. cnki.gsjtu. 2019. 000 666.

[26] Li, J., Huang, H.T., Zhou, G.P. (2017). A retrospective study on the evaluation of acute kidney injury caused by vancomycin in elderly patients using serum Cys-C and urine KIM-1 [J]. China Pharmacist, 20(12):2186-2189.

[27] Wang, C., Bai, Y.J., Zhou, X.B., et al. (2021). Research progress of urinary NGAL as a biomarker of drug-induced acute nephrotoxicity [J]. Drug Evaluation Research, 44(08): 1806-1810.

[28] Arthur, J.M., Hill, E.G., Alge, J.L., et al. (2014). Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery [J]. Kidney International, 85(2).

[29] Zhao, J. (2020). Screening of chronic kidney disease-related biomarkers and establishment of prediction models [D]. Tianjin Medical University. DOI:10.27366/ d.cnki. gtyku. 2020.000379.

[30] Yang, Z., Zhang, J., Tang, L.P. (2016). Relationship between serum RBP, NEFA, FKN levels and proteinuria excretion and glomerular filtration function damage in early diabetic nephropathy patients [J]. Journal of Hainan Medical University, 22(23):2822-2825. DOI: 10.13210/j.cnki.jhmu.20160929.006.

[31] Zhou, X., Zhang, H., Liu, Y. (2017). Combined Detection of Urinary Micro Albumin, α1-microglobulin and N-acetyl-β-D-glucosaminidase in the Early Diagnosis of Diabetic Nephropathy [J]. Pakistan Journal of Medical Sciences, 33(6).

[32] Yang, Z.X., Zhang, Y.G., Zhang, S.Y., et al. (2021). Analysis of the relationship between serum D-D, Kim-1 and urine RBP levels and disease severity and HOMA-IR in patients with diabetic nephropathy [J]. Labeled Immunoassays & Clinical Medicine, 28(08):1349-1352+1360.